After adjourning a merger vote four times in a month, Graf Acquisition IV in an 8-K today said its shareholders voted unanimously in favor of combining with NKGen Biotech. The vote was 9,502,928 shares cast to approve the deal, with zero opposition, according to the filing.
NKGen is a clinical-stage biotechnology company focused on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. NKGen is headquartered in Santa Ana, CA.
Following the most recent adjournment last week, Graf IV said NKGen agreed to waive the $50 million minimum cash requirement to close.
The SPAC said 3,386,528 shares were redeemed going into the vote, or roughly a third of shares then outstanding. Read more.
